Boothbay Fund Management, LLC Verona Pharma PLC Transaction History

Boothbay Fund Management, LLC

$3.27 Billion
Q4 2024

A detailed history of Boothbay Fund Management, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 432,170 shares of VRNA stock, worth $27.7 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

432,170

Previous 409,070 5.65%

Holding current value

$27.7 Million

Previous $11.8 Million 70.54%

% of portfolio

0.61%

Previous 0.33%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$28.71 - $47.02 $663,201 - $1.09 Million	23,100 Added 5.65%	432,170 $20.1 Million
Q3 2024 Nov 14, 2024	SELL	$15.46 - $30.16 $6.9 Million - $13.5 Million	-446,328 Reduced 52.18%	409,070 $11.8 Million
Q2 2024 Aug 14, 2024	BUY	$11.48 - $17.02 $2.48 Million - $3.68 Million	216,280 Added 33.84%	855,398 $12.4 Million
Q1 2024 May 15, 2024	BUY	$15.3 - $20.24 $8.74 Million - $11.6 Million	571,194 Added 840.93%	639,118 $10.3 Million
Q4 2023 Feb 14, 2024	BUY	$11.94 - $20.47 $140,008 - $240,031	11,726 Added 20.87%	67,924 $1.35 Million
Q3 2023 Nov 14, 2023	BUY	$16.3 - $22.09 $80,098 - $108,550	4,914 Added 9.58%	56,198 $916,000
Q2 2023 Aug 14, 2023	BUY	$19.41 - $23.43 $336,239 - $405,877	17,323 Added 51.01%	51,284 $1.08 Million
Q1 2023 May 15, 2023	SELL	$18.06 - $25.27 $70,939 - $99,260	-3,928 Reduced 10.37%	33,961 $681,000
Q4 2022 Feb 14, 2023	SELL	$9.84 - $26.13 $87,674 - $232,818	-8,910 Reduced 19.04%	37,889 $990,000
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $35,268 - $115,773	8,519 Added 22.25%	46,799 $478,000
Q2 2022 Aug 15, 2022	BUY	$3.55 - $5.06 $135,894 - $193,696	38,280 New	38,280 $160,000

Others Institutions Holding VRNA

# of Institutions

217

Shares Held

70.5M

Call Options Held

1.4M

Put Options Held

299K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $3.9B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Account

Boothbay Fund Management, LLC Verona Pharma PLC Transaction History